about
Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilizationPegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for patients after hematopoietic stem cell transplantationPegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilizationA combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Modelling chemotherapy effects on granulopoiesis.Pegylation: engineering improved biopharmaceuticals for oncology.Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.Agents under investigation for the treatment and prevention of neutropenia.Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: A systematic review and meta-analysis.Cytokine binding by polysaccharide-antibody conjugates.1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells.Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.Pegfilgrastim-induced hyperleukocytosis.Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs
P2860
Q24186269-F4D90B7A-8653-45AC-A526-AF95B956AA3BQ24201099-65AA6F32-D950-4499-8E00-8CC66BF80A1EQ24201219-F786B02D-7E37-4791-AB79-0512768636DCQ33712928-FA1E4CB0-7FB4-45B2-A451-118B9A51A6BEQ34996295-130E3EF7-AC33-4C7B-9C6C-3997048818D0Q35200818-DD5CBA06-CB49-4BE8-AB22-E0EE77BDFE15Q35200824-FA15AC71-2E47-4499-9948-C2A975FC4923Q36677460-679B2BAF-4F1E-42D0-92B2-FF50EB94D022Q36985881-ED826E58-4199-42D1-AB77-5F2B6118A964Q37391741-2A7B93EA-83F2-4C2C-BD57-E1061A746191Q37455829-C298F062-EBB0-4E43-B7CB-4443699D0707Q38068457-0057F726-7396-4C4B-A84B-D105870A13F6Q38315396-C5B0F8BD-5FC9-4F29-9B2C-B63F0648708EQ38796594-49BA62E3-2F4C-432A-AD0C-03B0B4A4F36CQ39665229-A832DC3A-E771-46C4-AE22-3975F97FC8E7Q41958401-FD0BB0B9-C074-4022-A15B-DCDC9B304966Q44019603-081BDAF2-8D3F-4C4F-8C2F-55CF065EC618Q44369683-C2A9EF22-2E0F-4995-BAB9-8C8706B84D02Q44435533-B8A416E3-0427-43B5-A19F-39F1BFB3BE8AQ47213188-342D8D36-4C6E-4722-818E-A56B1C2FA65DQ47657705-D63966E0-16FC-4103-A873-522F0B4E8012Q50990877-7B237DE6-4517-4F68-9EBA-E591467414F6Q51039067-11CED15E-D847-4463-B7DB-11136BB9B7C8Q51425302-6EA7E6BB-F111-437C-AAB3-81E83BAFC711Q54464834-D60388C4-9F67-42CE-9890-51FE827C0459Q55467897-DBF51A51-ECE1-4A2C-BD36-52DBC11EFDB8Q58869645-BB15C527-7BBC-45C6-9DB6-48540791216C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics of pegfilgrastim.
@ast
Pharmacokinetics of pegfilgrastim.
@en
type
label
Pharmacokinetics of pegfilgrastim.
@ast
Pharmacokinetics of pegfilgrastim.
@en
prefLabel
Pharmacokinetics of pegfilgrastim.
@ast
Pharmacokinetics of pegfilgrastim.
@en
P2860
P1433
P1476
Pharmacokinetics of pegfilgrastim.
@en
P2093
William C Zamboni
P2860
P304
P356
10.1592/PHCO.23.9.9S.32888
P407
P433
P577
2003-08-01T00:00:00Z